Vertex Pharmaceuticals’ Kidney Disease Drug Povetacicept Shows Promise in Late-Stage Trial
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) increased by 8.3% on Tuesday, March 10, 2026, after the company announced positive results from a late-stage trial for its experimental kidney disease drug, povetacicept. The drug targets IgA nephropathy, a rare autoimmune kidney disease.
Key Trial Findings
The Phase 3 RAINIER study demonstrated that povetacicept met its primary goal, showing a statistically significant and clinically meaningful reduction of approximately 50% in proteinuria – a key marker of kidney health – compared to a placebo. Vertex Pharmaceuticals reported these findings in an interim analysis at week 36.
the drug achieved key secondary endpoints, including a 79.3% drop in serum galactose-deficient IgA1 levels versus placebo. The treatment was also found to be safe and well-tolerated, with no serious adverse events reported and a low rate of study dropouts (0.8% in the povetacicept group versus 1.5% in the placebo arm). BioSpace
Regulatory Path and Analyst Outlook
Vertex Pharmaceuticals has a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for povetacicept and expects to complete its submission by the end of March 2026. BioSpace BMO Capital Markets analysts anticipate a potential FDA approval in November 2026, assuming a standard six-month priority review. Analysts from Leerink Partners described the data as “strong,” while BMO Capital Markets analysts expressed continued encouragement regarding the strength of povetacicept’s data as Vertex works to expand its business beyond cystic fibrosis.
About Povetacicept and IgA Nephropathy
Povetacicept is an investigational fusion protein designed to inhibit B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), two cytokines implicated in autoimmune kidney diseases. Nasdaq IgA nephropathy is a chronic condition that can lead to kidney failure.
Additional Data from the RUBY-3 Trial
Data from the ongoing open-label Phase 1/2 RUBY-3 trial, presented at the American Society of Nephrology (ASN) Kidney Week 2025, showed promising results in both IgA nephropathy and primary membranous nephropathy (pMN). In the IgAN cohort, treatment with povetacicept led to a 64% reduction in urine protein to creatinine ratio (UPCR) and stabilization of kidney function. In the pMN cohort, pove treatment resulted in an 82% reduction in UPCR. Nasdaq
Vertex Stock Performance
As of March 10, 2026, Vertex Pharmaceuticals’ shares are up 10.1% since the beginning of the year and are trading near their 52-week high. Investors who purchased shares five years ago have seen a return of approximately 132%.